We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
ExSyn and Exim-Indis will now represent simABs in the Indian and the U.S. markets respectively —bringing their innovative, high-quality antibodies to researchers, biotech companies, and healthcare providers.
simAbs: Smart Integrated Manufacturing of ATMP’s and Biologics
simAbs provides the full range of services and support for biologics development and GMP manufacturing, specializing in sustainable biomanufacturing technologies.
For more details, please visit:
https://www.simabs.com/
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Pyrazinamide is a first-line antitubercular drug used in combination therapy for the treatment of tuberculosis (TB). It is a synthetic pyrazine derivative and acts as a prodrug, which is converted into its active form (pyrazinoic acid) inside Mycobacterium tuberculosis.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
6-Bromopyridine-2,3-diamine is a heterocyclic organic compound belonging to the class of substituted pyridines. It is used mainly as an intermediate in pharmaceuticals and agrochemicals.